Related content

Toll-like receptor modulators: a patent review (2006 –– 2010)

By Basith Shaherin   Manavalan Balachandran   Lee Gwang   Kim Sang Geon   Choi Sangdun  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 6, 2011-06 ,pp. : 927-944

Informa Healthcare

Access to resources Recommend Favorite

Toll-like receptor 9 agonists as cancer therapeutics

By Holtick Udo   Scheulen Max E   von Bergwelt-Baildon Michael S   Weihrauch Martin R  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 3, 2011-03 ,pp. : 361-372

Informa Healthcare

Access to resources Recommend Favorite

Toll-Like Receptor Agonists as Adjuvants for HIV Vaccines

By  

Current Medicinal Chemistry, Vol. 18, Iss. 33, 2011-11 ,pp. : 5079-5082

Bentham Science Publishers

Access to resources Recommend Favorite

A Review of the Role of CpG Oligodeoxynucleotides as Toll-Like Receptor 9 Agonists in Prophylactic and Therapeutic Vaccine Development in Infectious Diseases

By Gupta Kaveri  

Drugs in R&D, Vol. 9, Iss. 3, 2008-01 ,pp. : 137-145

Adis International

Access to resources Recommend Favorite

Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections

By  

Anti-Infective Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Infective Agents), Vol. 10, Iss. 5, 2011-10 ,pp. : 327-338

Bentham Science Publishers

Access to resources Recommend Favorite